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Abstract
Background: The polo-like kinases (Plks) are a group of serine/threonine kinases which have roles
in many aspects of cellular function including the regulation of mitotic activity and cellular stress
responses. This study focuses on Plk4, the most divergent member of the Plk family, which is
necessary for proper cellular proliferation. More specifically, alterations in Plk4 levels cause
significantly adverse mitotic defects including abnormal centrosome duplication and aberrant
mitotic spindle formation. We sought to clarify the effect of reduced Plk4 levels on the cell by
examining transcript profiles of Plk4 wild-type and heterozygous mouse embryonic fibroblasts
(MEFs). Subsequently, the levels of several key proteins involved in the DNA damage response
were examined.
Results: 143 genes were found to be significantly up-regulated in the heterozygous MEFs
compared to their wild-type counterparts, while conversely, 9 genes were down-regulated.
Numerous genes with increased transcript levels in heterozygous MEFs were identified to be
involved in p53-dependent pathways. Furthermore, examination of the promoter regions of all upand down-regulated genes revealed that the majority contained putative p53 responsive elements.
An analysis of transcript levels in MEFs after exposure to either ionizing or ultraviolet radiation
revealed a significant change between wild type and heterozygous MEFS for Plk4 transcript levels
upon only UV exposure. Furthermore, changes in protein levels of several important cell checkpoint and apoptosis regulators were examined, including p53, Chk1, Chk2, Cdc25C and p21. In
heterozygous MEFs, p53, p21 and Chk2 protein levels were at significantly higher levels.
Furthermore, p53 activity was increased 5 fold in the Plk4 heterozygous MEFs.
Conclusion: Global transcript profiles and levels of key proteins involved in cellular proliferation
and DNA damage pathways were examined in wild-type and Plk4 heterozygous MEFs. It was
determined that Plk4 haploinsufficiency leads to changes in the levels of RNA accumulation for a
number of key cellular genes as well as changes in protein levels for several important cell cycle/
DNA damage proteins. We propose a model in which reduced Plk4 levels invoke an increase in
p53 levels that leads to the aforementioned changes in global transcription profiles.

Page 1 of 14
(page number not for citation purposes)

BMC Genomics 2009, 10:319

Background
Plk4 (Sak), is a member of the polo-like kinase (Plk) family of serine/threonine kinases which are involved in the
regulation of the cell cycle, cellular response to stress such
as DNA damage, and the duplication and maturation of
centrosomes [1-4]. Deregulation of the Plks by overexpression, depletion via epigenetic silencing or loss of heterozygosity (LOH) has implicated them in the
development of centrosome abnormalities and has been
associated with a CIN (chromosomal instability) phenotype and malignancy. Plk4 is a major regulator of centriole
duplication as indicated first by an increase in the number
of supernumerary centrosomes correlated with Plk4 overexpression, and second, by a reduction in centriole duplication with the eventual development of mono-polar
spindles upon repeated cell divisions observed after RNA
interference for Plk4 [5-8]. Homozygous null Plk4 mice
are embryonic lethal at ~E7.5 of development, with an
increase in the proportion of mitotic cells, whereas Plk4
heterozygous mice are phenotypically normal [9]. Interestingly aged Plk4 heterozygous mice display haploinsufficiency with tumours developing at a high frequency in
major sites such as the liver and lung [10]. Haploinsufficiency for Plk4 affects normal progression through the cell
cycle and maintenance of the genome. For example, in a
two thirds liver hepatectomy model, Plk4 heterozygous
hepatocytes had an increased rate of tri- and tetra-polar
spindle complexes with frequent mitotic errors as compared to those form wild-type regenerating livers [10]. At
9–12 months post-hepatectomy all the Plk4 heterozygous
mice had abnormal liver morphology and there was an
increased rate of tumourigenesis [10]. These results suggest that Plk4 haploinsufficiency potentially leads to
increased aneuploidy a likely tumour promoting event.
Plk4 loss also has implications in human malignancy,
where LOH for Plk4 was found in the majority of a small
sample of hepatocellular carcinomas [10].
Plks 1–3 in general all play important roles in the regulation of the cell cycle and the DNA damage response. Furthermore, several of their respective substrates are in
common, with the individual Plks likely placing their substrate under tighter or opposing control. For example,
both Plk3 and Plk1 phosphorylate Cdc25C and p53 by
targeting different residues in each case. Plk3 phosphorylates Cdc25C on serine 216 [11], a site that is also targeted by Chk1 and Chk2 [4,12]. Phosphorylation of
serine 216 of Cdc25C is inhibitory, which is due to
sequestration of the protein phosphatase in the cytoplasm
by 14-3-3 protein, thus blocking mitotic entry [13].
Human Cdc25C is phosphorylated on Ser-198 by Plk1,
part of an activation amplification loop that increases the
phosphatases activity to allow mitotic entry [14]. Pololike kinase 1 (Plk1) is known to inhibit p53 function by
physical interaction [15], while phosphorylation of p53 at
Ser 20 by Plk3 serves to functionally link DNA damage
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with increased p53 activity [16]. Chk2 is another protein
that is phosphorylated by the Plks. Plk1 interacts with,
phosphorylates and colocalizes with Chk1 [17], Plk3
phosphorylates Chk2 at two residues, which results in
subsequent phosphorylation of Chk2 on T68 by ATM in
response to DNA damage, thus upregulating Chk2 activity
[18,19].
Similar to the other Plk family members, which have
established roles in DNA damage pathways, Plk4 likely
functions within or is a target of DNA damage pathways.
This is supported by the observation that Plk4 interacts
with and phosphorylates p53 [10,20]. Plk4 expression is
repressed in a p53 dependent manner in response to DNA
damaging agents, with the p53 repression of Plk4 activity
occurring through the recruitment of a histone deacetylase
(HDAC) transcription repressor [21]. Additionally,
Cdc25C, a key regulator of the entrance into mitosis and
target of DNA damage proteins, is a substrate for Plk4
[22]. Significant phenotypic differences are also observed
between Plk4 wild-type and heterozygous mouse embryonic fibroblasts (MEFs) [10]. Contrary to what would be
expected, heterozygous Plk4 MEFs display a phenotype
typified by multiple centrosomes which lead to multipolar spindles, mitotic failure and delayed proliferation [10].
All the evidence published to date is consistent with a
model as suggested by Habendanck et al (2005) in which
reduced Plk4 activity causes occasional cellular division
failure as a result of aberrant centrosome duplication and
subsequent mitotic spindle malformation[7], This cell
division failure can lead to either aneuploidy or polyploidy, which could in turn contribute to the higher incidence of tumors in heterozygous mice. As an initial step
in further characterizing the effect of lower Plk4 levels on
the cell, we utilized microarrays to provide a general survey of differences in the transcript profiles of Plk4 wildtype and heterozygous MEFs. Here, we report on a spectrum of genes that are upregulated or downregulated in
the Plk4 heterozygous MEFs, including the key cell cycle
regulators p53, p21 and chk2 and the presence of
increased p53 levels/activity as a result of Plk4 haploinsufficiency.

Methods
Establishment of primary mouse embryonic fibroblasts
(MEFs)
Mouse embryonic fibroblast cell lines were established
from 12.5 day old wild-type and heterozygous Plk4
embryos as previously described [9]. All experiments utilizing mice as well as embryos and cell lines derived from
them were performed in accordance to CCAC guidelines
and approved by the University of Windsor Animal Care
Committee. The MEFs were cultured in Dulbecco's Modified Eagles Medium (Sigma) containing 20% fetal bovine
serum (Sigma), 1% penicillin-streptomycin (Gibco) and
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250 ug/ml gentamicin (Gibco) and maintained at 37°C
with 5% CO2. All experiments were performed with MEFs
at passage 2–3.
Flow cytometry
Wild type and heterozygous mouse embryonic fibroblasts
were grown to approximately 80% confluency. The MEFs
were then harvested, fixed in 80% ice-cold ethanol,
stained with PI and the cell cycle profiles were determined
by flow cytometry on a Beckman Coulter Cytomics FC
500 flow cytometer. Flow cytometry results were analyzed
using Cytomics RXP Analysis software (Beckman Coulter). Presented results are based on three independent
experiments.
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(GAPDH), Prohibitin, Sap30 Binding Protein (SAP30BP),
and Wnt-Inducible Signaling Pathway Protein (WISP1)
and the size of their respective products are summarized
in Table 1. PCR was performed using Hot Start Taq DNA
Polymerase (Qiagen) and the results of each amplification
were normalized to the GAPDH internal control.
Exposure of MEFs to DNA damaging agents
Wild-type and heterozygous MEFs were exposed to ultraviolet light (UV) at 40 mJ/cm2 using a GS Gene Linker UV
Chamber (Biorad) or ionizing radiation (IR) of 25 Gy
using a RX-650 Cabinet X-ray System (Faxitron) and RNA
or protein was isolated from the MEFs at the specified
time points.

Microarray analysis
MEF cells were grown asynchronously to a confluency of
70–80% with total RNA isolation performed using the
RNeasy Mini Kit (Qiagen). In order to confirm the integrity and quality of the RNA, the RNA was run on the 2100
Bioanalyzer (Agilent) using the RNA 6000 Nano Assay
Kit. Total RNA extracted from MEFs was subjected to
microarray analysis at the University Health Network
(UHN) Microarray Centre in Toronto. The samples were
labeled using the UHN's standard indirect labeling protocol and hybridized to a Mouse 22.4K chip. Results are
based on three independent replicates with subsequent
analysis performed using "The Institute for Genomic
Research (TIGR) microarray software suite".

Western blot analysis
Cells were lysed in lysis buffer (50 mM Tris-Cl, 100 mM
Nacl, 500 mM EDTA, 1% Triton-X), the cell lysate was
cleared by centrifugation and equal amount of total protein was loaded into 8% (or 12%) SDS-PAGE gels. Following separation, proteins were transferred onto a PVDF
membrane, and Western blot analysis was performed
using standard methods. The primary antibodies were as
follows, anti-p53 (Sigma), anti-Chk2 (Sigma), anti-Chk1,
(Sigma), anti-p21 (BD Pharmingen), anti-Cdc25C (Santa
Cruz) and anti-GAPDH (Cell Signalling). The secondary
antibodies were as follow: anti-mouse HRP (Amersham),
anti-rabbit HRP (Amersham) and were used at dilutions
recommended by manufacturers.

Semi-quantitative RT-PCR
Reverse transcription (RT) was performed using Superscript II Reverse Transcriptase (Invitrogen) as per the manufacturer's instructions. All forward and reverse primers
for PCR were designed to span intron/exon boundaries in
order to prevent amplification of contaminating genomic
DNA in the cDNA mixture. Primers for the amplification
of Plk4, glyceraldehyde 3-phosphate dehydrogenase

Apoptosis assay
The level of apoptosis was determined in heterozygous
and wild-type Plk4 MEFs using a TdT-mediated dUTP
Nick-End Labeling (TUNEL) assay as per the manufacturer's provided protocol (Promega). Cells were exposed
to 40 mJ/cm2 to induce UV mediated DNA damage and
analyzed 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr post radiation.
Results are based on three independent experiments.

Table 1: Oligonucleotide primer sequences for RT-PCR analysis.

Gene

Primers

Size (bp)

GAPDH

Forward 5'GCTGAGTATGTCGTGGAGTCT-3'
Reverse 5'-CAGAGCTGAACGGGAAGCTC-3'

410

Plk4

Forward 5'-AGGGAAGCTAGGCACTTCATG-3'
Reverse 5'-GGAAGACCACCTTTTGAC-3'

310

Sap30

Forward 5'-CCAGAAGCTCTACGAGCGGAA-3'
Reverse 5'TGGTCTGAAGACTCCTACTATGAG-3'

190

Prohibitin

Forward 5'-CGTATCTACACCAGCATTGGC-3'
Reverse 5'-TGTGGTGGAAAAGGCTGAGC-3'

301

Wisp1

Forward 5'-GCCTAATCACAGATGGCTGTG-3;
Reverse 5'-CAATAGGAGTGTGTGCACAGGTG-3'

150
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X-gal senescence staining
MEFs were grown to 70–80% confluency and then stained
using a β-Galactosidase Staining Kit (Cell Signalling).
Cells were washed in PBS, fixed in a 2% formaldehyde
solution and incubated overnight in 20 mg/ml X-gal
staining solution. Senescent cells were identified by the
presence of a typical perinuclear blue stain.
p53 activity assay
The activity of p53 from Plk4 heterozygous and wild-type
MEFs was analyzed with the Active p53 Activity Assay Kit
(R*#38;D Systems). Cells were grown to 70–80% confluency and 5 ug of nuclear extracts (equal amounts of protein were determined by Bradford assay, Biorad) were
subjected to the capture ELISA assay as per the manufacturer's protocol. Absorbance measurements were performed at 450 nm on a Victor 1420 Spectrophotometer.
Results are based on three independent experiments and
normalized to the wild-type controls.

Results and discussion
Comparison between transcript profiles in wild-type and
heterozygous Plk4 MEFs using microarray
A number of phenotypic differences have been observed
between wild-type and heterozygous Plk4 MEFs [10]. For
example, heterozygous MEFs exhibit a growth rate
approaching one half that of their wild-type counterparts
[10]. Many of these cells contain multiple centrosomes,
micronuclei and mitotic defects [10]. In the present study
we examined the cell cycle profiles of Plk4 heterozygous
MEFs in comparison to wild-type MEFs and found that
the heterozygous MEFS displayed a decrease in cells in

G0/G1 and an increase in the number of cells in G2/M
(Figure 1). These results suggest that Plk4 haploinsufficiency may also lead to impaired progression through the
cell cycle with the potential to lead to abnormal chromosomal alignment and segregation. Plk4 haploinsufficiency
and loss of heterozygosity have also been implicated in
the development of primary hepatocellular carcinoma in
mice and humans respectively [10].
The main focus of the present study was to examine global
changes in transcript profiles between Plk4 wild type and
heterozygous MEFs. In order to accomplish this, we utilized independent cultures of asynchronously growing
age matched Plk4 wild-type and heterozygous MEFs in
three replicates. Quantification and normalization of the
data was performed using "The Institute for Genomic
Research" (TIGR) TM4 microarray data analysis suite.
Normalization and filtering of the data was performed
using the TIGR Microarray Data Analysis System (MIDAS)
application. Analysis of all microarray data sets for the different microarray experiments (ex. Wild-type Plk4 MEFs vs
Heterozygous Plk4 MEFs) were performed independently.
K-means clustering analysis was performed using TIGR
Multiexperiment Viewer (MEV). Within each cluster,
genes having a log ratio value greater than 1 or less than 1 on each microarray chip were identified. Genes having a
log ratio greater than 1 represented genes in the heterozygous MEFs that have at least a two fold increase in gene
expression. As the wild-type MEFs was used as the control,
genes with a log ratio greater than 1 were classified as upregulated in the heterozygous MEFs and genes with a log

Plk4+/+ MEFs

Plk4+/- MEFs

52.36%

46.30%
33.28%

39.87%

0.9%

1.7%

13.55%

Number

Number

12.80%

DNA content

DNA content

Figure
Cell
cycle
1 profile of Plk4 heterozygous and wild-type MEFs
Cell cycle profile of Plk4 heterozygous and wild-type MEFs. Presented are typical cell cyle profiles of asynchronous
populations of Plk4 heterozygous and wild-type MEFs based on flow cytometry of propidium iodide stained cells. The data is
representative of three independent experiments.
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ratio less -1 represented genes in the wild-type MEFs that
have at least a two fold increase in gene expression or are
down-regulated in the heterozygous MEFs.

overexpression has been implicated in cellular morphological transformation [29] and hepatocellular carcinoma
[30].

From the microarray data, 9 genes were identified as having at least a two-fold decrease in transcript levels in the
heterozygous MEFs when compared to the wild-type control (Table 2), while 143 genes were identified as having
at least a two-fold increase in transcript levels in the heterozygous MEFs (Table 2). We ordered these genes within
each functional group based on the average fold difference between Plk4 wild-type and heterozygous MEFs. In
order to test the validity of the microarray results we
assessed transcript levels for Plk4 and three arbitrary genes
with at least a two-fold increase in expression by qualitative RT-PCR. A graphic representation of these results is
shown in Figure 2A. In confirmation of previously published results [10], Plk4 transcripts levels in the heterozygous Plk4 MEFs are at about 60% of the level seen in
wild-type MEFs. Furthermore, Prohibitin, Wisp1 and
Sap30 are upregulated in the Plk4 heterozygous MEFs thus
independently confirming their altered expression profile
as identified by microarray results.

The observation that the expression levels of genes
involved in p53 dependent pathways were altered, coupled with the known interaction of p53 with Plk4, and
since changes in p53 levels, like Plk4, may also contribute
to centrosome abnormalities [24,31,32], led us to further
analyze this result. We therefore analyzed the promoter
region of both the up and downregulated genes utilizing
the MAPPER search engine [33,34] and found that the
majority of these genes contained numerous p53 responsive elements within the first 5 kilobases upstream of the
transcriptional start site. Furthermore, several of these
upregulated genes are known p53 targets (including msh2
[35]) or affect the p53 transcriptional machinery (like
CDK8 [36]).

The presumed major cellular function for each down or
up-regulated gene was identified using annotation data
from the PubMed database, and/or the Online Mendelian
Inheritance in Man (OMIM) database. Furthermore, we
utilized GenMAPP 2 [23] and Panther [24] to identify global biological trends in our gene expression data. The few
genes that were downregulated in Plk4 heterozygous MEFs
functionally included genes involved in development and
metabolism. Far more genes were upregulated than were
downregulated in the heterozygous MEFs. These included
genes with a spectrum of known functions such as cell
cycle control, the DNA damage response, DNA repair, epigenetic modification, development, and transcription/
translation. In particular, several key genes involved in
p53 dependent pathways, Rho signaling, Wnt signaling
and the proteasome were upregulated in the heterozygous
MEFs. Several of these genes have been implicated in
malignancy and are of particular interest given the
increased rate of malignancy previously identified in Plk4
heterozygous mice. This includes securin (Pttg1) which
serves to prevent premature chromosome separation
through inhibition of separase activity. Securin is involved
in several key cellular events including mitosis, cell cycle
progression, DNA repair and apoptosis. Furthermore,
securin (Pttg1) is upregulated in several malignancies and
in particularly, pituitary adenomas [25]. Casein Kinase II
(Csnk2a1), a serine/threonine kinase is a positive regulator of Wnt signalling pathway that is also upregulated in
most cancers [26]. Phosphatidylinositol 3-kinase
(Pic3c2a) is an upstream regulator of Akt [27], both of
which are aberrantly regulated in many cancer types and
as such are prime targets for intervention [28], Wisp1

The effect of ionizing and ultraviolet radiation on the Plk4
transcript and protein profiles in MEFs
The Plks are known components of DNA damage pathways, affecting levels and activity of a number of key proteins including p53, Chk2, Cdc25C and others. Plk4 is
known to interact with proteins involved in the response
to DNA damage including p53 [20], Cdc25C [22] and
Chk2 [37]. This characteristic, coupled with the observation that many of the upregulated genes contain numerous p53 responsive elements within their promoter, led us
to examine the effect of DNA damaging agents on the levels of key genes involved in the DNA damage response in
the context of Plk4 levels. Wild-type and heterozygous
MEFs were exposed to 25 Gy IR or 40 mJ/cm2 UV and
changes in transcript levels were analyzed by semi-quantitative RT-PCR. In response to IR, we found no significant
difference in Plk4 transcript levels between wild-type and
heterozygous MEFs (Figure 2B). In contrast, upon exposure to UV, there is a striking difference in transcript profile levels of Plk4 between Plk4 wild-type and
heterozygous MEFs (Figure 2C). Initially, post exposure to
UV, Plk4 transcripts are undetectable in both wild-type
and heterozygous MEFs. Interestingly two hours post UV
exposure plk4 transcripts levels in the wild-type MEFs
returned to control levels and then subsequently increase
to 40% greater expression, while no Plk4 transcripts are
detectable in the heterozygous MEFs. Unfortunately, we
were unable to detect Plk4 protein in these MEFs with the
commercially available antibodies. As our array results
suggest that p53 activity may be increased in the Plk4 heterozygotes, we were therefore interested in examining p53
protein levels. We found a sharp contrast between wildtype and heterozygous MEFs, with levels of p53 protein
expression substantially higher in the heterozygotes (Figure 3a). These results would seem to suggest that the levels
of p53 in the heterozygous MEFs may be the result of
DNA damage that occurs as a result of genomic instability.
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Fold Increase
(mRNA expression)

A

2.5
2
1.5
Plk4+/+ MEFs
1
Plk4+/- MEFs
0.5

B

Relative mRNA Expression

0

Plk4

Prohibitin

Wisp1

SAP30BP

1.2
1
0.8
0.6
0.4
0.2

Time post IR
radiation:

0hr

2hrs

4hrs

6hrs

8hrs

Time post UV
radiation:
control

0hr

2hrs

4hrs

6hrs

8hrs

C

Relative mRNA Expression

control

2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2

Figure
Comparison
2 of transcript levels between Plk4 heterozygous and wild-type MEFs
Comparison of transcript levels between Plk4 heterozygous and wild-type MEFs. A) Confirmation of microarray results. Semi-quantitative RT-PCR was carried out to measure the relative difference in the expression of Plk4 and the
candidate genes prohibitin, wisp1 and sap30bp in Plk4 wild-type and heterozygous MEFs. Values in each case were normalized
to the levels of GAPDH transcript. Presented data are a result of three independent experiments. B) Relative levels of Plk4
transcript post ionizing radiation (IR). MEFs were exposed to 25 Gy IR and RNA was isolated at the indicated time points
post exposure followed by RT-PCR to measure the relative abundance of Plk4 transcript (as above). C) Relative levels of
Plk4 transcript post ultraviolet radiation (UV). MEFs were exposed to 40 J/Cm2 UV and RNA was isolated at the indicated time points post exposure followed by RT-PCR to measure the relative abundance of Plk4 transcript (as above).
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Gene ID

Fold Change

Casein kinase II (Csnk2a1)

12995

5.8040

Protein phosphatase 1F
(PP2C domain containing)
(Ppm1f)
Squamous cell carcinoma
antigen recognized by Tcells 1 (Sart1)
Origin recognition complex,
subunit 4-like (Orc4l)
Inhibitor of DNA binding 2
(Id2)
Protein phosphatase 5
(Ppp5c)
heme binding protein 2
(Hebp2)
Neuropilin (Nrp1)

68606

4.8644

20227

Putative p53 site Metabolism

Gene ID

Fold Change

20 N-acylsphingosine
amidohydrolase (acid
ceramidase) like (Asahl)
10 Leucyl/cystinyl
aminopeptidase (Lnpep)

11886

6.0539

14

240028

4.8539

6

4.6888

20 Galactose-4-epimerase
(Gale)

74246

4.7700

8

26428

4.5661

217666

4.6257

15

15902

4.4323

286922

4.2976

27

65179

4.0765

54371

4.2926

18

56016

3.8955

433667

3.9806

16

18186

3.0956

310395

3.7939

14

Prohibitin (Phb)

18673

3.0459

19085

3.3199

18

Cyclin dependent kinase 8
(Cdk8)
Heterogeneous nuclear
ribonucleoprotein C
(Hnrpc)
TVMSFG fibroblast growth
factor receptor 1 precursor
(Fgfr1)
Phosphatidylinositol 3kinase (Pic3c2a)
Pituitary tumortransforming 1 (Pttg1)
Development
Sal-like 3 (Sall3)

264064

3.0094

9 L-2-hydroxyglutarate
dehydrogenase (L2hgdh)
11 Fatty acid desaturase 3
(Fads3)
15 Carbohydrate
sulfotransferase 2 (Chst2)
10 Stearoyl-Coenzyme A
desaturase 1 (Ankrd13c)
13 CCR4 carbon catabolite
repression like 4 (Ccrn4l)
18 protein kinase, cAMP
dependent regulatory, type I
beta (Prkar1b)
17 DNA Repair

15381

2.5962

8 Uracil-DNA glycosylase
(Ung)

22256

4.1846

15

14182

2.2643

18 MutS homolog 6 (Msh6)

17688

2.1811

23

18704

2.1636

21665

2.0156

10

30939

1.9518

9 Thymine DNA glycosylase
(Tdg)
11

20689

7.9335

4.8072

18

T-cell factor 4 (Rab27b)

80718

4.7804

4.1537

9

Nuclear receptor corepressor 1 (Ncor1)
Inositol 1,4,5-triphosphate
receptor 5 (Itpr2)

20185

4.4658

4.0003

20

16439

3.6909

3.7483

9

Transcriptional/Translational Regulation
13 Cysteinyl-tRNA synthetase
27267
(Cars)
14 Zinc Finger Protein 451
98403
(Zfp451)
16 Tetratricopeptide repeat
66827
domain 1 (Ttc1)
10 Highly similar to
12914
CBP_MOUSE CREB-binding
protein (Crebbp)

Putative p53 site
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Table 2: Transcripts up and down regulated in Plk4 heterozygous MEFs.

12835

3.5828

207165

3.3594

22402

3.2886

T-box transcription factor
Tbx15 (Tbx15)
Nuclear factor I/X (Nfix)

21384

2.9248

18032

2.8883

Thrombospondin 2 (Thbs2)

21826

2.5437

Osteopontin (Spp1)

20750

2.4717

Fukuyama type congenital
muscular dystrophy
homolog (Fktn)
DNA Methylation
SAP30 binding protein
(Sap30bp)
SET domain ERG-associated
histone methyltransferase
(Olfml3)
Calcium binding and coiled
coil domain 1 (Calcoco1)

246179

2.2362

57230

2.9834

99543

67488

15 Zinc finger protein 689
(Zfp689)
NA Glutamyl-prolyl-tRNA
synthetase (Eprs)
22 GC-rich sequence DNAbinding factor homolog
isoform 1 (C21orf66)
13 Phenylalanine-tRNA
synthetase 2 (Fars2)
9 GLIS family zinc finger 3
(Glis3)
23 Transmembrane and
tetratricopeptide repeat
containing 2 (Tmtc2)
15 Transcription factor A
(Tfam)
9

71131

3.4636

17

107508

3.3065

19

67367

3.0984

N/A

69955

3.0678

13

226075

2.6233

10

278279

2.2096

18

21780

2.0680

14

Cellular/Ion Transport
8 Pleckstrin (Plek)

56193

6.0575

11

2.0889

9 Syntaxin 18 (Stx18)

53407

5.0970

18

5.6489

19 Aquaporin-1 (Aqp1)

11826

4.4128

16

21366

4.4110

18

211446

3.9296

10

14760

3.8281

21

227059

3.5028

13

14299
68607
27411

3.1881
3.1718
3.0842

15
17
14

21855

2.7129

19

233726

2.5873

17

100273

2.5501

12

11941

2.4328

26
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Miscellaneous Cellular Functions
Coiled Coil domain
containing 131 (Ccdc131)
Thyroid hormone receptor
interactor 11 (Trip11)
Smg-6 homolog (Smg6)
Talin 2 (Tln2)
Tomoregulin 1 (Tmeff1)

216345

6.4372

11

109181

5.8691

NA

103677
70549
230157

5.3375
5.2780
5.1116

11
N/A
7

Channel-interacting PDZ
domain protein (Inadl)

12695

4.9504

14

WD repeat domain 50
(Utp18)
Inositol hexaphosphate
kinase 1 (Ip6k1)
Spetex-2E protein
(100040875)

217109

4.9252

16

27399

4.8086

12

4.6574

N/A

Solute carrier family 6
(Slc6a6)
Exocyst complex component
3 (Exoc3)
Protein-coupled receptor 19
(Gpr19)
Solute carrier family 39
(Slc39a10)
Frequenin homolog (Freq)
Serine Hydrolase like (Serhl)
Solute carrier family 14
(Slc14a2)
Translocator of inner
mitochondrial membrane
(Timm17b)
Similar to crooked neck
protein (Ipo7)
Oxysterol binding protein
like protein 9 (Osbpl9)
ATPase, Ca++ transporting,
plasma membrane 2 (Atp2b2)

Page 8 of 14

Procollagen, type VI, alpha 3
(Col6a3)
Fetal Alzheimer antigen
(Bptf)
WNT1 inducible signaling
pathway protein 1 (Wisp1)

(page number not for citation purposes)
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Table 2: Transcripts up and down regulated in Plk4 heterozygous MEFs. (Continued)

17475

4.0596

Myosin heavy chain 10
(Myh10)
CDC42 effector protein
(Rho GTPase binding) 2
(Cdc42ep2)
Zinc finger protein 507
(Zfp507)
aarF domain containing
kinase 1 (Adck1)
AHNAK nucleoprotein
(Ahnak)
Ring finger protein 11
(Arhgdia)
Villin (Vil1)

77579

3.8880

12 Transient receptor potential
cation channel, subfamily M,
member 7 (Trpm7) 58800
11

104252

3.5581

23 Downregulated Genes

668501

3.4688

72113

3.4641

66395

3.2688

192662

3.1199

22349

2.9808

3-phosphoglycerate
dehydrogenase (Phgdh)
Arginine/serine-rich coiledcoil 1 (Rsrc1)
Olfactory receptor 202
(Olfr202)

236539

2.9427

66880

2.9404

258997

2.9278

Discs, large homolog 5
(Dlg5)
2'-phosphodiesterase
(E430028B21Rik)

71228

2.9094

HD domain containing 3
(Hdcc3)
Heat shock protein
1(Heatr1)
Myotubularin related
protein 7 (Mtmr7)
Mitochondrial ribosomal
protein L50 (Mrpl50)
Proteasome(macropain)26S
subunit, non-ATPase
(Psmd4)
NICE-5 protein (AA414768)

68695

2.7345

217995

2.7243

54384

2.4370

8

362517

2.2540

20

19185

2.2031

11

245350

2.1272

N/A

2.8426

1.9917

11

N/A Development
9 Procollagen, type III, alpha 1
(Col3a1)
20 Procollagen, type V, alpha 2
(Col5a2)
25 Oral-facial-digital syndrome 1
gene homolog (Ofd1)
15 Procollagen, type I, alpha 2
(Col1a2)
18 Metabolism

12825

-4.6364

6

12832

-4.1420

12

237222

-3.0782

8

12843

-2.9648

12

6 Stearoyl-Coenzyme A
desaturase 2 (Scd2)
7 Mus musculus mVL30-1
retroelement mRNA
sequence (mVL30-1)
N/A Transmembrane protein 34
(Tmem184c)
0 Mus musculus 0 day neonate
cerebellum cDNA
(E430024C06Rik)
14 Hypothetical protein
LOC639390 (LOC639390)
13

20250

-2.4729

10

-2.5566

N/A

234463

-2.5241

14

319443

-2.3000

N/A

-2.2121

N/A

Shown above are ninety-seven upregulated genes and nine downregulated genes in the heterozygous MEFs. "Fold change" is the change in transcript level in the heterozygous MEFs relative to
wild-type MEFs as determined by microarray analysis. The "Putative p53 sites" are as determined by MAPPER and is based on the first 5000 nucleotides upstream of the transcriptional start site.
Please note that forty-six downregulated transcripts and their corresponding gene were omitted from the table as they encode hypothetical proteins or have unknown cellular functions. All the
microarray data has been deposited into the MIAME database under accession number E-MEXP-2161.
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Multiple PDZ domain
protein (Mpdz)
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Plk4 heterozygote MEFs when compared to wild-type (Figure 3c). Consistent with this result, in our microarray
data, p21 transcript levels were also upregulated 1.95
times (just below our arbitrarily chosen 2 fold cut-off) in
the Plk4 heterozygous MEFs. Additionally, six hours post
DNA damage we observed a substantial increase in p21
levels in the wild-type MEFs, while there was no further
increase apparent in the heterozygous MEFs post DNA
damage. The observation that p21 protein and transcript
levels were elevated in the heterozygous MEFs again corresponds with the aforementioned increased levels of p53.
Furthermore, it is also consistent with the increased levels
of CDK8 transcripts found in the heterozygous MEFs
(Table 2). CDK8 binding to p53 target genes is known to
correlate positively with transcriptional strength. CDK8 is
recruited to the p21 locus during conditions of strong p21
transcriptional activation [36]. We found minimal differences in the detectable levels of Cdc25C (Figure 3d) and
Chk1 (Figure 3e) prior to or post treatment.

Figure 3 ofand
Comparison
heterozygous
protein
wild-type
levelsMEFs
upon DNA damage between
Comparison of protein levels upon DNA damage
between heterozygous and wild-type MEFs. Heterozygous and wild-type Plk4 MEFs were exposed to 25 Gy IR or
40 mJ/cm2 UV. Six hours post exposure cell extracts were
subjected to Western Blot analysis. Shown are representative data from 3 repeats. GAPDH was used as a loading control to ensure equal protein loading.

We also examined p53 levels in these cells after exposure
to DNA damaging agents based on the differences found
for Plk4 transcript levels 6 hrs post exposure. In the case of
UV we did not see any additional increase in the level of
p53 protein compared to the Plk4 wild-type and heterozygote controls. In contrast, the levels of p53 in the wildtype MEFs increased to the heterozygote levels when
exposed to IR. The levels were stabilized at close to maximal levels for these conditions and increased insignificantly. Results displayed are the representative data from
three independent experiments. We subsequently examined the levels of a number of known cell cycle control
and DNA damage response proteins. Chk2, which is
known to aid in the maintenance of sustained G1, G2/M
arrest, and apoptosis by phosphorylating p53 [12,38-41],
was also at much higher levels in the heterozygous MEFs
pretreatment (Figure 3b). Upon exposure to UV or ionizing radiation the levels of Chk2 were elevated in both
wild-type and heterozygous MEFs. We next examined the
levels of p21, a downstream effector and transcriptional
target of p53 and found that the levels were increased in

The effect of UV induced DNA damage on apoptosis and
cell cycle profiles in Plk4 MEFs
As p53 is a major regulator of apoptosis we were next
interested in determining whether the levels of apoptosis
were higher in the Plk4 heterozygous MEFs. Since we
observed a large decrease in the level of plk4 transcripts in
heterozygous MEFs upon UV exposure and since UV is a
more effective inducer of both p53 activity and apoptosis
than IR [42] we examined the levels of apoptosis after UV
treatment. Interestingly, we found no significant difference in the levels of apoptosis for wild-type and heterozygous MEFs prior to or post treatment with UV (Figure
4A). While we were surprised that there was no difference
in the level of apoptosis between wild-type and heterozygous MEFs, it is consistent with the elevated level of
Wisp1 mRNA seen in the heterozygous MEFs. Wisp1 is
known to attenuate p53 mediated apoptosis through the
activation of PKB/Akt anti-apoptotic pathways [43]. This
results in the protection of cells from the late stages of p53
mediated apoptosis. Additionally, while the cell cycle profiles of wild-type and heterozygous MEFs were different
without treatment, their respective responses to UV irradiation were similar with an overall increase in the Sub G0
population post exposure (Figure 4B).
Senescence and p53 activity in Plk4 MEFs
In most cell types p53 is a potential key regulator of senescence growth arrest, the maintenance of senescence
growth arrest and the initiation of the senescence
response following DNA damage [44]. In order to address
the possibility that elevated p53 levels may be correlated
with a senescent phenotype in the Plk4 heterozygous
MEFs, we stained the cells for β-galactosidase activity from
passages 2–5 (see additional file 1). We found no evidence of increased β-galactosidase activity in the Plk4 het-
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100
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B
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S
G2/M
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70
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20
10

Time post UV
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Plk4+/+

Plk4+/-
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Plk4+/+

6hrs
Plk4+/-

Plk4+/+

8hrs
Plk4+/-

Plk4+/+

Plk4+/-

Assessment
Figure 4 of levels of apoptosis and cell cycle arrest in heterozygous and wild-type Plk4 MEFs
Assessment of levels of apoptosis and cell cycle arrest in heterozygous and wild-type Plk4 MEFs. A.) Levels of
apoptosis after UV induced DNA damage in Plk4 heterozygous and wild-type MEFs. Apoptosis was analyzed prior
to and after UV induced DNA damage (40 mJ/cm2) with a TUNEL assay. The results are presented as a percentage of apoptosis
positive cells and are representative of three independent experiments. B.) Effect of UV induced DNA damage in Plk4
heterozygous and wild-type MEFs on progression through the cell cycle. Cell cycle profiles were analyzed prior to
and after UV induced DNA damage (40 mJ/cm2) by flow cytometry after staining of the DNA with propidium iodide. The population of cells in G0/G1, S, G2/M and Sub G0 are displayed as percentage and are representative of three independent experiments.
erzoygous MEFs relative to the wild type MEFs; thus
suggesting that the elevated p53 protein levels in the Plk4
heterozygous MEFs were not correlated with an increase
in cellular senescence.
p53 accumulation and activity is regulated by post-translational modification of at least 20 sites via protein phos-

phorylation
and/or
other
post-translational
modifications [42]. As previously stated, the p53 protein
levels are markedly increased in the Plk4 heterozygous
MEFs compared to wild-type. It was therefore of interest to
determine whether the increase in p53 levels was also
accompanied by an increase in p53 activity. In order test
this possibility we utilized an enzyme-linked immunoPage 11 of 14
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A
Fold Increase
(p53 activity)

6
5
4
3
2
1

Plk4+/+ MEFs

Plk4+/- MEFs

Plk4+/+ MEFs
+competing oligos

Plk4+/- MEFs
+competing oligos

B
Plk4 heterozygous MEFs

Plk4 wild type MEFs
normal Plk4 levels

reduced Plk4 levels

Plk4

Plk4
p53 regulated genes

???

DNA
Damage
(genomic
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p53 regulated genes
???

Chk2

p53

levels

Plk4

DNA
Chk2
Damage
(genomic
instability)
transcriptional
repression

p53

levels

p21

levels

Plk4
p21

p53
Figure
activity
5 and model of Plk4 and p53 interactions in Plk4 heterozygous MEFs
p53 activity and model of Plk4 and p53 interactions in Plk4 heterozygous MEFs. A.) Effect of Plk4 haploinsufficiency on p53 activity. p53 transcriptional activity was analyzed in Plk4 heterozygous and wild-type MEFs from nuclear
extracts using a capture ELISA assay. The p53 specificity was confirmed upon incubation with competing labeled and unlabeled
oligonucleotides. The results were normalized against wild-type control and are representative of three independent experiments. B.) Model of p53 and Plk4 regulation in Plk4 heterozygous and wild-type MEFs. Shown are proposed Plk4/
p53 direct/indirect interactions in Plk4 wild-type and heterozygous MEFs with the resultant corresponding changes in protein
levels, activity and gene expression. Solid lines indicate pathways that are functionally active, whereas dotted lines indicate pathways with reduced activity.
sorbent assay (ELISA) to measure p53 transcriptional
activity in our Plk4 wild-type and heterozygous MEFS.
Interestingly, in agreement with the presence of p53
responsive elements in the genes that were upregulated in
the array data, we observed a 5 fold increase in p53 activity in the heterozygous MEFs (Figure 5A).

We propose that the increased p53 protein levels and
activity that occur as a result of Plk4 haploinsufficiency
may in turn contribute to the over-expression of numerous genes containing p53 responsive elements within
their promoters (Figure 5B). The function of these genes
encompasses a spectrum of cellular activities including
Page 12 of 14
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cell cycle control and the response to DNA damage. The
results suggest that one function of Plk4 phosphorylation
of p53 may be with respect to p53 protein stability and/or
activity. In this scenario the possibility exists that this
arises through a direct effect in which lower Plk4 levels
result in reduced phosphorylation of p53 by Plk4 thus
leading to an increase in protein p53 stability and activity.
Alternatively, the presence of supernumerary centrosomes
seen in Plk4 heterozygous MEFs may lead to an increase in
genomic instability and the induction of checkpoints to
deal with the ensuing DNA damage. Very few targets for
Plk4 have been identified thus far. However, the possibility exists that the increased levels of p53 and phenotypic
changes observed occur as a result of indirect consequences of Plk4 haploinsufficiency and targeting of other
substrates. For example, one known plausible indirect
effect of Plk4 haploinsufficiency could be through Chk2.
Plk4 both interacts with and phosphorylates Chk2, a key
regulator of the DNA damage response and p53 [37].
Conceivably, reduced phosphorylation of Chk2 as a result
of lower Plk4 levels may result in altered Chk2 levels and/
or activity towards p53 thus resulting in p53's increased
stability or activity. This is consistent with the observation
that Chk2 levels are greatly increased in the heterozygous
MEFs and the observation that the cell cycle profiles of
heterozygous MEFs are altered.
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Ultraviolet; WISP1: Wnt Inducible Signaling Pathway protein.
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Conclusion
In conclusion, our results demonstrate that Plk4 haploinsufficiency leads to changes in the levels of RNA accumulation for a number of key cellular genes as well as changes
in protein levels for several important cell cycle/DNA
damage proteins. The majority of the upregulated genes
have numerous p53 responsive elements within their promoter regions, thus suggesting that Plk4 haploinsuficiency directly or indirectly leads to an increase in p53
activity in MEFs. Further studies should reveal the nature
of the relationship between Plk4 levels, p53 and the down
and upregulated genes found in Plk4 heterozygous MEFs.
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